Developer docs
API playgroundTry for free, no card

Search company profiles

Savonix

Full company profile

uuid0000krk

Namestring
Savonix
Websiteurl
savonix.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Savonix is a San Francisco-based digital health company founded in 2015 that operates in the cognitive and behavioral assessment segment. Per its own positioning, it offers what it describes as the world's first clinical, evidence-based, all-mobile digital assessment of cognitive and emotional function, targeting use cases where traditional neuropsychological testing has been the standard. The company has built a small organization (11–50 employees) led by a clinically-credentialed team, including a PhD founder/former CEO, a PhD Chairman, a Chief Science Officer with a DPhil, and a CTO.

The product architecture centers on delivering cognitive and emotional assessments through a mobile interface, replacing or supplementing paper-based or clinician-administered neuropsychological batteries. Savonix's clinical positioning is reinforced by the scientific leadership composition and a roster of healthcare-focused investors (notably DigiTx Partners, a digital health specialist), suggesting the company targets regulated healthcare buyers — clinicians, health systems, payers, and potentially pharmaceutical sponsors running cognitive endpoint studies. Total disclosed funding across seed, Series A, and Series B rounds from 2015 through April 2019 is approximately $16.2 million.

The company's revenue model and pricing structure are not disclosed in the available source data. There is no published pricing model, no named customer logos, and no disclosed ARR or revenue figure. The company's primary public website currently displays only a loader/verification page, providing no further business-model detail. Combined with a headcount band of 11–50 and the last recorded capital event in April 2019, this suggests a small commercial-stage organization whose monetization mechanics — whether enterprise SaaS licensing, per-assessment fees, pharma trial contracts, or payer partnerships — cannot be determined from the input.

Short descriptiontext

Savonix is a San Francisco-based digital health company, founded in 2015, that delivers a clinical, evidence-based, all-mobile digital assessment of cognitive and emotional function, serving clinicians, health systems, payers, and pharmaceutical researchers as potential customers in the neuropsychological assessment market.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Francisco, United States
HQ citystring
San Francisco
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
digital cognitive assessment, neurocognitive testing software, brain health screening, mobile clinical assessment, digital health platform
Industry1 code
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)
NAICS code2 codes
  • Other Computer Related Services541519
  • Custom Computer Programming Services541511
SIC code2 codes
  • Services-Prepackaged Software7372
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Digital Cognitive Assessment
Social media profiles2 records
Cost components4 values
Personnel, Technology or R&D, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Savonix provides an all-mobile, digital assessment platform that clinically and evidence-based evaluates cognitive and emotional function. The product is designed for use by clinicians, researchers, and healthcare organizations to measure neurocognitive performance via mobile devices, eliminating the need for specialized in-clinic testing equipment.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Savonix Cognitive Assessment Platform
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Linus Health offers a digital cognitive assessment platform combining iPad-based testing with AI for early detection of dementia and other neurological conditions. It is a direct peer to Savonix in evidence-based digital cognitive assessment for clinical and research use.

TypeDirect peer
Description

Neurotrack develops digital cognitive health tools for screening and monitoring memory and cognitive decline. It overlaps directly with Savonix in mobile cognitive assessment aimed at early detection and longitudinal monitoring.

TypeDirect peer
Description

Cogstate provides computerized cognitive assessment tools used in clinical trials, healthcare, and research. It is the most direct competitor to Savonix, offering validated digital cognitive testing across similar end markets including pharma-sponsored trials and clinical care.

TypeDirect peer
Description

ImPACT Applications offers computerized cognitive testing tools widely used in concussion management and clinical research. It is a direct peer in computerized neurocognitive assessment with overlapping use cases in clinical and sports-medicine settings.

TypeEmerging player
Description

Akili Interactive develops FDA-cleared digital therapeutics for cognitive dysfunction, including ADHD and multiple sclerosis. It is an emerging peer adjacent to Savonix, focused on prescription digital therapeutics rather than assessment, but operating in the same cognitive-health category.

TypeDirect peer
Description

Altoida provides a digital cognitive assessment platform using augmented reality and AI on smartphones and tablets for early detection of cognitive impairment. It is a direct peer pursuing the same mobile-first, evidence-based cognitive assessment positioning as Savonix.

7Pear Therapeutics
TypeBroad incumbent
Description

Pear Therapeutics was a pioneer in prescription digital therapeutics (PDT) across multiple therapeutic areas including CNS. It is a broad incumbent reference point for the digital therapeutics/SaMD category in which Savonix operates, illustrating both the opportunity and the commercial challenges of evidence-based digital therapeutics.

TypeDirect peer
Description

CNS Vital Signs provides a computerized neurocognitive assessment battery used by clinicians and researchers. It is a direct peer to Savonix in clinical-grade computerized cognitive testing for healthcare and research customers.

TypeDirect peer
Description

Cambridge Cognition develops digital cognitive assessments for clinical research and healthcare. It is a direct peer to Savonix, serving pharma, academic, and clinical customers with validated computerized neurocognitive tests.

TypeDirect peer
Description

BrainCheck offers a digital cognitive assessment and brain health platform for clinicians and health systems. It competes directly with Savonix in mobile/tablet-based cognitive screening deployed in primary care and specialty neurology.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights4 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Savonix

Digital Cognitive Assessmentsavonix.com

Savonix is a San Francisco-based digital health company, founded in 2015, that delivers a clinical, evidence-based, all-mobile digital assessment of cognitive and emotional function, serving clinicians, health systems, payers, and pharmaceutical researchers as potential customers in the neuropsychological assessment market.

What Savonix does

Savonix is a San Francisco-based digital health company founded in 2015 that operates in the cognitive and behavioral assessment segment. Per its own positioning, it offers what it describes as the world's first clinical, evidence-based, all-mobile digital assessment of cognitive and emotional function, targeting use cases where traditional neuropsychological testing has been the standard. The company has built a small organization (11–50 employees) led by a clinically-credentialed team, including a PhD founder/former CEO, a PhD Chairman, a Chief Science Officer with a DPhil, and a CTO.

The product architecture centers on delivering cognitive and emotional assessments through a mobile interface, replacing or supplementing paper-based or clinician-administered neuropsychological batteries. Savonix's clinical positioning is reinforced by the scientific leadership composition and a roster of healthcare-focused investors (notably DigiTx Partners, a digital health specialist), suggesting the company targets regulated healthcare buyers — clinicians, health systems, payers, and potentially pharmaceutical sponsors running cognitive endpoint studies. Total disclosed funding across seed, Series A, and Series B rounds from 2015 through April 2019 is approximately $16.2 million.

The company's revenue model and pricing structure are not disclosed in the available source data. There is no published pricing model, no named customer logos, and no disclosed ARR or revenue figure. The company's primary public website currently displays only a loader/verification page, providing no further business-model detail. Combined with a headcount band of 11–50 and the last recorded capital event in April 2019, this suggests a small commercial-stage organization whose monetization mechanics — whether enterprise SaaS licensing, per-assessment fees, pharma trial contracts, or payer partnerships — cannot be determined from the input.

Savonix firmographics

Firmographics
Name
Savonix
Website
https://savonix.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Savonix is a San Francisco-based digital health company, founded in 2015, that delivers a clinical, evidence-based, all-mobile digital assessment of cognitive and emotional function, serving clinicians, health systems, payers, and pharmaceutical researchers as potential customers in the neuropsychological assessment market.
Ownership category
akta.pro rank

Savonix industry classification

Industry
Product category
Digital Cognitive Assessment
NAICS
Other Computer Related Services (541519), Custom Computer Programming Services (541511)
SIC
Services-Prepackaged Software (7372), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACANAI
Behavioral Health & Neurocognitive Therapeutics (Digital)
Healthcare & Life Sciences/Digital Health & Health IT/Digital Therapeutics (DTx) & Software as a Medical Device (SaMD)

Keywords

  • Digital cognitive assessment
  • Neurocognitive testing software
  • Brain health screening
  • Mobile clinical assessment
  • Digital health platform

Where Savonix is headquartered

Location

Headquarters

HQ city
San Francisco
HQ country
United States
HQ region
North America

Markets served

Savonix business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations

Savonix product offering

Product offering

Core offering

Savonix provides an all-mobile, digital assessment platform that clinically and evidence-based evaluates cognitive and emotional function. The product is designed for use by clinicians, researchers, and healthcare organizations to measure neurocognitive performance via mobile devices, eliminating the need for specialized in-clinic testing equipment.

Differentiator

Problem solved

Functional benefit

Products and services

  • Savonix Cognitive Assessment Platform

Companies that use Savonix

Customer profile

Ideal customer profiles1 record

Savonix technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Savonix partnerships and signals

Strategic signal

Recent moves5 records

Expansion highlights3 records

Savonix competitors and assessment

Company assessment

Direct peers

  • Linus Health: Linus Health offers a digital cognitive assessment platform combining iPad-based testing with AI for early detection of dementia and other neurological conditions. It is a direct peer to Savonix in evidence-based digital cognitive assessment for clinical and research use.
  • Neurotrack: Neurotrack develops digital cognitive health tools for screening and monitoring memory and cognitive decline. It overlaps directly with Savonix in mobile cognitive assessment aimed at early detection and longitudinal monitoring.
  • Cogstate: Cogstate provides computerized cognitive assessment tools used in clinical trials, healthcare, and research. It is the most direct competitor to Savonix, offering validated digital cognitive testing across similar end markets including pharma-sponsored trials and clinical care.
  • ImPACT Applications: ImPACT Applications offers computerized cognitive testing tools widely used in concussion management and clinical research. It is a direct peer in computerized neurocognitive assessment with overlapping use cases in clinical and sports-medicine settings.
  • Altoida: Altoida provides a digital cognitive assessment platform using augmented reality and AI on smartphones and tablets for early detection of cognitive impairment. It is a direct peer pursuing the same mobile-first, evidence-based cognitive assessment positioning as Savonix.
  • CNS Vital Signs: CNS Vital Signs provides a computerized neurocognitive assessment battery used by clinicians and researchers. It is a direct peer to Savonix in clinical-grade computerized cognitive testing for healthcare and research customers.
  • Cambridge Cognition: Cambridge Cognition develops digital cognitive assessments for clinical research and healthcare. It is a direct peer to Savonix, serving pharma, academic, and clinical customers with validated computerized neurocognitive tests.
  • BrainCheck: BrainCheck offers a digital cognitive assessment and brain health platform for clinicians and health systems. It competes directly with Savonix in mobile/tablet-based cognitive screening deployed in primary care and specialty neurology.

Emerging players

  • Akili Interactive: Akili Interactive develops FDA-cleared digital therapeutics for cognitive dysfunction, including ADHD and multiple sclerosis. It is an emerging peer adjacent to Savonix, focused on prescription digital therapeutics rather than assessment, but operating in the same cognitive-health category.

Broad incumbents

  • Pear Therapeutics: Pear Therapeutics was a pioneer in prescription digital therapeutics (PDT) across multiple therapeutic areas including CNS. It is a broad incumbent reference point for the digital therapeutics/SaMD category in which Savonix operates, illustrating both the opportunity and the commercial challenges of evidence-based digital therapeutics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights4 records

Customer concentration

Savonix social profiles

Digital presence

Savonix financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Savonix leadership team

Management profile

Number of profiles

Profiles6 records

Savonix funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Savonix M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Savonix

What does Savonix do?

Savonix provides an all-mobile, digital assessment platform that clinically and evidence-based evaluates cognitive and emotional function. The product is designed for use by clinicians, researchers, and healthcare organizations to measure neurocognitive performance via mobile devices, eliminating the need for specialized in-clinic testing equipment.

When was Savonix founded?

Savonix was founded in 2015. It employs 11 to 50 people.

Where is Savonix based?

Savonix is headquartered in San Francisco, United States, in the North America region.

Who are Savonix's main competitors?

Direct peers on record are Linus Health, Neurotrack, Cogstate, ImPACT Applications, Altoida, CNS Vital Signs, Cambridge Cognition and BrainCheck. Akili Interactive is listed as an emerging player. Pear Therapeutics is listed as a broad incumbent.

Does Savonix have an API?

No public API is recorded for Savonix.

What industry is Savonix in?

Savonix's product category is Digital Cognitive Assessment. Its primary akta.pro industry code is HLACANAI, Behavioral Health & Neurocognitive Therapeutics (Digital). Its NAICS code is 541519 and its SIC code is 7372.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
IndiaWeb2Savonix and Fujitsu Connected Technologies Limited Partner to Introduce Savonix Mobile App on Raku-Raku Smartphone F-42ASavonix and Fujitsu Connected Technologies launched Savonix Mobile, a cognitive testing app, on the Raku-Raku Smartphone F-42A. The app tests eight brain functions and detects mild cognitive impairment 93% of the time. Japan's dementia cases are projected to rise to 7.3 million by 2025.Pulse 2.0Neurocognitive Assessment Company Savonix Adds $9.6 Million To Funding RoundSavonix raised $9.6 million in Series A extension financing, bringing the total round to $14.7 million. The funding will accelerate growth and market expansion into the US and Asia, and develop features for its Savonix Mobile cognitive assessment platform. New investors include Fusion Fund and Wavemaker Partners.FinSMEsSavonix Closes $9.6M Series A Extension RoundSavonix, a cognitive health company, closed a $9.6M Series A extension, bringing total funding to $14.7M. The round was co-led by Fusion Fund and Wavemaker Partners, with new board members joining. Funds will accelerate growth and market expansion in the US and Asia.FinSMEsSavonix Raises $5.1M in Series A FundingSavonix, a neurocognitive testing company, raised $5.1M in Series A funding led by DigiTx Partners, bringing total financing to $6.6M. The funds will support global expansion, including Japan and China, and investment in a data science and product team.FinSMEsSavonix Raises $5.1M in Series A FundingSavonix, a San Francisco-based digital neurocognitive testing company, raised $5.1 million in Series A funding led by DigiTx Partners with participation from Rethink Impact. The company intends to use the capital to expand into global markets such as Japan and China while developing additional medical partnerships and enhancing its data science team.GlobeNewswireSavonix Announces Key Partnerships with Leading Life Sciences Companies to Establish a Global Standard for Digital Cognitive AssessmentSavonix announced partnerships with NYU, CereScan, Proove Biosciences, Alkahest, and Senescence Life Sciences to establish a global standard for digital cognitive assessment. The company also raised $5.1 million in Series A funding, bringing total financing to $6.6 million. The partnerships aim to validate its mobile cognitive assessment platform.GlobeNewswireSavonix Raises $5.1 Million to Modernize Neurocognitive Testing and Transform Patient CareSavonix raised $5.1 million in a Series A round led by DigiTx Partners, bringing total financing to $6.6 million. The funds will support global expansion, including Japan and China, and development of partnerships and a data science team. The company plans to expand its reach across the United States and worldwide.MedCity NewsSavonix raises seed funding to get a snapshot of your brain with cognitive assessment appSavonix raised $1.5 million in seed funding to commercialize its digital cognitive screening tool for stress, depression, anxiety, and memory issues. The round, led by RoundGlass Partners, will fund staff and launch the app, which uses smartphone-based tasks to assess cognitive function.